CIRAANO: Multimodal exploration of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.

Prior treatment

• [MCI-AD] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) at non-stabilized doses within 8 weeks prior to the inclusion visit
• [D-AD, LBD & svPPA] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) and/or L-DOPA for LBD patients, at non-stabilized doses within 8 weeks prior to the inclusion visit
• [all participants except informants] Chronic use of medications that affect cognition and/or may interfere with cognitive or imaging assessments (including non-tricyclic antidepressants, anticonvulsants such as lamotrigine, pregabalin, levetiracetam ; atypical antipsychotics; short-/intermediate-acting benzodiazepines such as alprazolam, lorazepam, oxazepam, temazepam; and sedative antihistamines), if doses were not stabilized within the 6 weeks prior to inclusion (except for changes due to withdrawal treatment in AUD patients)
• [all participants except informants] Participation in a clinical study involving exposure to ionizing radiation within the year prior to inclusion
• [all participants except informants] Current use of long-acting benzodiazepines, typical antipsychotics, tricyclic antidepressants, or first-generation antihistamines at the time of inclusion (unless related to withdrawal treatment in AUD patients), with discontinuation of such medication less than 3 months prior to inclusion
• [ACT & ATHL] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) at non-stabilized doses within 8 weeks prior to the inclusion visit

Other illness

• [D-AD, LBD & svPPA] Absence of a caregiver or informant (i.e., a trusted person or relative who will be present from inclusion through the assessments, for patients with major cognitive impairment)
• [AUD & AMN] Evidence suggesting a probable neurodegenerative disorder (e.g., impairment in instrumental cognitive functions)
• [all participants except informants] Known hypersensitivity to Amyvid® or Tauvid®
• [all participants except informants] History of neurological or neurosurgical conditions that could significantly affect cognitive function and/or neuroimaging (e.g., head trauma with loss of consciousness >30 minutes, stroke, multiple sclerosis, insulin coma)
• [all participants except informants] Schizophrenia, psychotic disorders, or bipolar disorders (according to DSM-5 criteria)
• [all participants except informants] Presence of untreated chronic or acute illnesses (respiratory, cardiovascular, gastrointestinal, renal, metabolic, hematologic, endocrine, or infectious)

Other

• [all participants except informants] Pregnant or breastfeeding women
• [all participants except informants] Presence of contraindications to MRI (e.g., claustrophobia, ferromagnetic objects in the body) or to Amyvid® and Tauvid® PET scans.
• [SCD] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
• [MCI-AD] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
• [D-AD, LBD & svPPA] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
• [D-AD, LBD & svPPA] Inability to understand instructions
• [AUD & AMN] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
• [NARCO] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
• [all participants except informants] Current participation in a clinical trial and/or other research involving human participants (RIPH) if it includes imaging examinations using radiotracers
• [all participants except informants] Having a score suggesting an alcohol dependence (>9) on the FACE questionnaire (except for AUD patients)
• [all participants except informants] Physical, behavioral, or geographical limitations preventing participation in the study
• [all participants except informants] Refusal to cooperate during assessments
• [HC] Current or recent (within the last 5 years) theater practice
• [HC] Presence of depressive symptoms (MADRS score > 19, threshold for moderate depression)
• [ACT & ATHL] Presence of depressive symptoms (MADRS score > 19, threshold for moderate depression)

• [all participants] Minimum education level of 7 years (at least equivalent to the French Certificat d’Études Primaires (CEP))
• [HC] Aged 18 or older
• [HC] Neuropsychological performance within the normal range for age and education level on all inclusion battery tests (±1.65 standard deviation)
• [HC] Be considered capable of complying with the protocol according to the investigator's judgment
• [ATHL] Aged 18 or older
• [ATHL] Must have participated in a memory competition—international, European, or national level
• [ATHL] Be considered capable of complying with the protocol according to the investigator's judgment
• [SCD] Aged 60 or older
• [SCD] Recruited from memory clinics
• [SCD] Must meet recognized criteria for subjective cognitive decline in the context of the preclinical stage of Alzheimer’s disease
• [MCI-AD] Aged 60 or older
• [all participants] Native French speaker and educated in French
• [MCI-AD] Recruited from memory clinics
• [MCI-AD] Must meet current recognized clinical criteria for mild cognitive impairment due to Alzheimer’s disease
• [D-AD] Aged 60 years or older
• [D-AD] Recruited from memory clinics
• [D-AD] Meeting current and recognized clinical criteria for major neurocognitive disorder due to probable Alzheimer’s disease
• [LBD] Aged 60 years or older
• [LBD] Recruited from memory clinics
• [LBD] Meeting current and recognized clinical criteria for probable Lewy body dementia or probable prodromal Lewy body dementia (mild cognitive impairment with Lewy bodies)
• [svPPA] Aged 50 years or older
• [svPPA] Recruited from memory clinics
• [all participants] Affiliated with a French social security scheme or beneficiary of such a scheme
• [svPPA] Meeting current and recognized clinical criteria for semantic dementia
• [AUD] Aged 18 years or older
• [AUD] Recruited from an addiction treatment service
• [AUD] Undergoing treatment primarily for an alcohol use disorder at the time of inclusion
• [AUD] Detoxified, with withdrawal symptoms resolved (Cushman score <3, Cushman et al., 1985) and benzodiazepines discontinued at the time of inclusion
• [AUD] Abstinent from all psychoactive substances (except tobacco and prescribed medication) at the time of inclusion
• [AMN] Aged 18 years or older
• [AMN] Recruited from hospital services or residential facilities housing patients with non-degenerative amnesic syndromes
• [AMN] Presenting with major cognitive impairment : Characterized primarily by severe episodic memory deficits (anterograde amnesia), possibly associated with retrograde amnesia and/or other impairments ; Leading to significant impacts on daily functioning and reduced autonomy ; Persistent and stable over time
• [NARCO] Aged 18 years or older
• [all participants] Willingness to undergo several days of assessments
• [NARCO] - Diagnosed with type 1 narcolepsy according to the 3rd edition of the International Classification of Sleep Disorders (ICSD-3), which includes daytime sleepiness persisting for more than 3 months, and either : Presence of cataplexy, mean sleep latency <8 minutes on the Multiple Sleep Latency Test (MSLT), and at least two REM sleep onsets (on MSLT and/or overnight polysomnography) ; Or cerebrospinal fluid hypocretin level <110 pg/mL.
• [Informant] Aged 18 years or older
• [Informant] Spending at least one day per week with a relative included in one of the patient groups
• [all participants] Adherence to lifestyle considerations
• [all participants] Signed informed consent to participate in the study
• [ACT] Aged 18 or older
• [ACT] Must have performed in at least one theatre play in the last three years
• [ACT] Must be or have been a professional actor, either freelance or permanent (e.g., in a theatre company or at the Comédie-Française) for at least 5 years